GSK Highlights from ATS
Mortality data from the IMPACT study
Speaker Dr David A Lipson. GSK, Collegeville, Pennsylvania; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Potential mechanisms of mortality reduction
Speaker Professor David Singh is Professor of Clinical Pharmacology and Respiratory Medicine at the University of Manchester, United Kingdom
The molecules may explain the mortality benefit.
Speaker Professor Neil Barnes GSK, Brentford Middlesex, UK; Barts and the London School of Medicine and Dentistry, London, UK.
Other GSK clinical data from ATS
INTREPID: Investigation of Trelegy Effectiveness: Usual Practice Design
Clinical effectiveness of once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol versus multiple-inhaler triple therapy in usual clinical practice
Speaker Professor David Halpin is Consultant Physician and Honorary Associate Professor in Respiratory Medicine at the Royal Devon and Exeter Hospital, Exeter, UK
The EMAX trial: Early MAXimal bronchodilation for improving COPD stability
Predicting improvements in COPD with clinically important improvements in patient reported outcomes: a post hoc analysis of the EMAX trial.
Speaker Professor Claus Vogelmeier, MD, Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany